Nachrichten |
| Datum / Uhrzeit |
Titel |
Bewertung |
| 22.08.25 08:59:09 |
Ein Investor fordert eine Umwälzung bei Gerresheimer Packaging. |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Okay, here's a summary of the text within 400 words, followed by a German translation:
**Summary (English)**
A significant new shareholder, dubbed “active ownership,” has initiated a push for a radical overhaul of Gerresheimer, the German medical-packaging group. Following their acquisition of a 5.31% stake with options to increase it further, the investor is demanding a full strategic review, primarily focused on rapidly selling Gerresheimer’s moulded glass division. This sale is intended to significantly boost cash flow and dramatically reduce the company’s debt.
The investor’s actions come amid a challenging year for Gerresheimer, with its share price down approximately 36% year-to-date, despite a minor recovery today. Beyond the moulded glass divestment, they are requesting substantial portfolio restructuring, aggressive cost reductions, and the creation of a dedicated strategy committee. The overarching goal is to increase Gerresheimer’s return on sales by five percentage points.
This intervention highlights a broader trend of activist investors targeting companies across the healthcare and packaging sectors. Similar campaigns have been launched against medtech providers and pharmaceutical developers, all seeking strategic shifts and improved performance metrics. Gerresheimer itself has previously faced pressure from asset value investors. The speed with which the moulded glass division is being sold—initiated earlier this year—adds urgency to the situation.
The demand for a strategy committee suggests a need for greater oversight and a formalized process for evaluating ongoing projects. The investor’s arrival signals increased pressure on Gerresheimer's management to deliver tangible results and demonstrate a commitment to value creation.
---
**German Translation:**
**Zusammenfassung (Deutsch)**
Ein neuer, bedeutender Anteilseigner, der als “aktiver Anteilseigner” bezeichnet wird, hat eine radikale Umstrukturierung von Gerresheimer, dem deutschen Medizinpaketerzeuger, in Gang gesetzt. Nach der Akquisition von 5,31 % mit Optionen zur weiteren Erhöhung der Beteiligung fordert der Investor eine umfassende strategische Überprüfung, die sich hauptsächlich auf den schnellen Verkauf der durchgehenden Glasabteilung von Gerresheimer konzentriert. Dieser Verkauf soll die Cashflow-Situation deutlich verbessern und die Verschuldung des Unternehmens drastisch reduzieren.
Die Forderungen kommen inmitten einer schwierigen Phase für Gerresheimer, wobei der Aktienkurs im Jahresverlauf um rund 36 % gesunken ist, trotz einer geringfügigen Erholung heute. Neben dem Verkauf der durchgehenden Glasabteilung fordert der Investor eine umfassende Portfoliorestrukturierung, aggressive Kostensenkungen und die Einrichtung eines dedizierten Strategieausschusses. Das übergeordnete Ziel ist es, den Return on Sales von Gerresheimer um fünf Prozentpunkte zu erhöhen.
Diese Intervention spiegelt einen wachsenden Trend von Aktivinvestoren wider, die Unternehmen in den Bereichen Gesundheitswesen und Verpackung zielen. Ähnliche Kampagnen wurden gegen Medizintechnikhersteller und Pharmaunternehmen gestartet, um strategische Veränderungen und verbesserte Leistungskennzahlen zu erzwingen. Gerresheimer war bereits zuvor durch Asset Value Investoren unter Druck gesetzt worden. Die Geschwindigkeit, mit der die durchgehende Glasabteilung verkauft wird – die bereits Anfang des Jahres gestartet wurde – erhöht die Dringlichkeit der Situation.
(Die Übersetzung ist so gestaltet, dass sie die gleiche Information wie der englische Originaltext vermittelt). |
| 12.08.25 21:25:24 |
Gerresheimer AG: Achim Schalk beim Gerresheimer Vorstand |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Kommentare anzeigen. |
| 07.08.25 11:02:56 |
Gerresheimer (ETR:GXI) Aktionäre haben vor fünf Jahren einen Verlust von 52 % an Investitionen in den Lagerbestand erl |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Entdecken Sie Gerresheimers Fair Values aus der Gemeinschaft und wählen Sie Ihre
Im Allgemeinen ist langfristige Investition der Weg zu gehen. Aber auf dem Weg werden einige Bestände schlecht funktionieren. Die Gerresheimer AG (ETR:GXI) konnte im Laufe von fünf Jahren um 54 % sinken. Wir fühlen uns sicher für Aktionäre, die in der Nähe der Spitze gekauft. Und einige der jüngeren Käufer sind wahrscheinlich auch besorgt, mit dem Lager fallen 54% im letzten Jahr. Darüber hinaus ist es in etwa einem Viertel um 27% zurück. Das ist nicht viel Spaß für Halter.
Lassen Sie uns also einen Blick werfen und sehen, ob die langfristige Leistung des Unternehmens im Einklang mit dem Fortschritt des zugrunde liegenden Unternehmens steht.
AI wird die Gesundheitsversorgung verändern. Diese 20 Bestände arbeiten an allem von der Frühdiagnostik bis zur Drogenentdeckung. Der beste Teil - sie sind alle unter $10bn in marktcap - es gibt noch Zeit, in früh zu bekommen.
Es ist nicht zu leugnen, dass die Märkte manchmal effizient sind, aber die Preise spiegeln nicht immer die zugrunde liegende Geschäftsentwicklung wider. Durch den Vergleich von Gewinnen pro Aktie (EPS) und Preisänderungen im Laufe der Zeit können wir das Gefühl bekommen, wie sich Investor Einstellungen zu einem Unternehmen im Laufe der Zeit verändert haben.
Gerresheimer wurde in den letzten fünf Jahren profitabel. Die meisten würden das als eine gute Sache betrachten, also ist es kontra-intuitiv, den Aktienpreis zu senken. Andere Metriken können den Kurswechsel besser erklären.
Wir glauben nicht, dass die 0,09% im Aktienkurs ein großer Faktor sind, da es ziemlich klein ist, wie Dividenden gehen. Der Umsatz ist im Laufe der Zeit tatsächlich um 9,9% gestiegen. Es scheint also, dass man sich die Grundlagen genauer ansehen muss, um zu verstehen, warum der Aktienkurs verlangsamt. Schließlich kann es eine Gelegenheit geben.
Der Umsatz und das Ergebnis des Unternehmens (über die Zeit) sind im Bild unten dargestellt (klicken Sie auf die genauen Zahlen). XTRA: GXI Ergebnis- und Umsatzwachstum 7. August 2025
Gerresheimer ist ein bekannter Bestand, mit viel Analystabdeckung, was eine Sichtbarkeit in zukünftiges Wachstum nahelegt. Sie können sehen, was Analysten für Gerresheimer in dieser interaktiven Darstellung zukünftiger Gewinnschätzungen vorhersagen.
Was ist mit Dividends?
Neben der Messung der Aktienpreise sollten Investoren auch die Gesamtaktionärsrendite (TSR) berücksichtigen. Während die Aktienkursrendite nur die Veränderung des Aktienpreises widerspiegelt, umfasst die TSR den Wert der Dividenden (unter der Annahme, dass sie reinvestiert wurden) und den Nutzen einer diskontierten Kapitalerhöhung oder Spin-off. Für Unternehmen, die eine großzügige Dividende zahlen, ist die TSR oft viel höher als die Aktienkursrendite. Wir weisen darauf hin, dass für Gerresheimer die TSR in den letzten 5 Jahren -52% betrug, was besser ist als die oben erwähnte Aktienkurserklärung. Dies ist weitgehend auf die Dividendenzahlungen zurückzuführen!
Geschichte geht weiter
Eine andere Perspektive
Während der breitere Markt im letzten Jahr rund 26 % erreichte, verlor Gerresheimer Anteilseigner 54 % (auch Dividenden). Selbst die Aktienpreise guter Aktien fallen manchmal, aber wir wollen Verbesserungen in den grundlegenden Metriken eines Unternehmens sehen, bevor wir zu interessiert. Bedauerlicherweise hat die Performance im letzten Jahr einen schlechten Lauf, mit den Aktionären einen Gesamtverlust von 9% pro Jahr über fünf Jahre. Generell kann die langfristige Aktienpreisschwäche ein schlechtes Zeichen sein, obwohl kontrarianische Investoren den Bestand in der Hoffnung auf eine Wende erforschen wollen. Während es sich lohnt, die unterschiedlichen Auswirkungen zu berücksichtigen, die Marktbedingungen auf den Aktienkurs haben können, gibt es andere Faktoren, die noch wichtiger sind. Betrachten Sie zum Beispiel die immer gegenwärtige Art des Investitionsrisikos. Wir haben 4 Warnzeichen mit Gerresheimer identifiziert (mindestens 1 was uns etwas unangenehm macht), und sie zu verstehen, sollten Teil Ihres Investitionsprozesses sein.
Wir mögen Gerresheimer besser, wenn wir einen großen Insider kaufen. Während wir warten, checken Sie diese kostenlose Liste von unterschätzten Aktien (meist kleine Kappen) mit erheblichen, kürzlich, Insider-Käufen.
Bitte beachten Sie, dass die in diesem Artikel zitierten Marktrendite die gewogenen durchschnittlichen Renditen von Aktien widerspiegeln, die derzeit an deutschen Börsen gehandelt haben.
Haben Sie Feedback zu diesem Artikel? Über den Inhalt? Kontaktieren Sie uns direkt. Alternativ, E-Mail Editorial-team (at) einfachwallst.com.
Dieser Artikel von Simply Wall St ist allgemein in der Natur. Wir liefern Kommentare basierend auf historischen Daten und Analystenprognosen nur unter Verwendung einer unvoreingenommenen Methodik und unsere Artikel sind nicht als Finanzberatung gedacht. Es stellt keine Empfehlung dar, Aktien zu kaufen oder zu verkaufen, und berücksichtigt nicht Ihre Ziele oder Ihre finanzielle Situation. Wir wollen Ihnen langfristig fokussierte Analyse durch grundlegende Daten bringen. Beachten Sie, dass unsere Analyse möglicherweise nicht in den neuesten preisempfindlichen Unternehmensankündigungen oder qualitativen Material ausschlaggebend ist. Einfach Wand St hat keine Position in den genannten Beständen.
Kommentare anzeigen |
| 18.07.25 04:48:14 |
There May Be Reason For Hope In Gerresheimer's (ETR:GXI) Disappointing Earnings |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
The market for Gerresheimer AG's (ETR:GXI) shares didn't move much after it posted weak earnings recently. We did some digging, and we believe the earnings are stronger than they seem.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.XTRA:GXI Earnings and Revenue History July 18th 2025
How Do Unusual Items Influence Profit?
Importantly, our data indicates that Gerresheimer's profit was reduced by €22m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Gerresheimer doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Gerresheimer's Profit Performance
Because unusual items detracted from Gerresheimer's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Gerresheimer's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Gerresheimer, you'd also look into what risks it is currently facing. To help with this, we've discovered 4 warning signs (1 is potentially serious!) that you ought to be aware of before buying any shares in Gerresheimer.
Today we've zoomed in on a single data point to better understand the nature of Gerresheimer's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View comments |
| 30.06.25 11:13:09 |
A Look At The Intrinsic Value Of Gerresheimer AG (ETR:GXI) |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Key Insights
The projected fair value for Gerresheimer is €53.81 based on 2 Stage Free Cash Flow to Equity With €48.08 share price, Gerresheimer appears to be trading close to its estimated fair value Analyst price target for GXI is €70.50, which is 31% above our fair value estimate
Today we will run through one way of estimating the intrinsic value of Gerresheimer AG (ETR:GXI) by taking the expected future cash flows and discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Step By Step Through The Calculation
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (€, Millions) -€77.4m €48.9m €86.9m €132.0m €137.0m €140.8m €144.1m €147.0m €149.6m €152.0m Growth Rate Estimate Source Analyst x6 Analyst x5 Analyst x4 Analyst x2 Analyst x1 Est @ 2.78% Est @ 2.32% Est @ 2.01% Est @ 1.79% Est @ 1.63% Present Value (€, Millions) Discounted @ 7.5% -€72.0 €42.3 €70.0 €99.0 €95.6 €91.4 €87.0 €82.6 €78.3 €74.0
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = €648m
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.3%. We discount the terminal cash flows to today's value at a cost of equity of 7.5%.
Story Continues
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = €152m× (1 + 1.3%) ÷ (7.5%– 1.3%) = €2.5b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €2.5b÷ ( 1 + 7.5%)10= €1.2b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is €1.9b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of €48.1, the company appears about fair value at a 11% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.XTRA:GXI Discounted Cash Flow June 30th 2025
The Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Gerresheimer as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.5%, which is based on a levered beta of 1.430. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
See our latest analysis for Gerresheimer
SWOT Analysis for Gerresheimer
Strength
No major strengths identified for GXI.
Weakness
Earnings declined over the past year.
Interest payments on debt are not well covered.
Dividend is low compared to the top 25% of dividend payers in the Life Sciences market.
Opportunity
Annual earnings are forecast to grow faster than the German market.
Current share price is below our estimate of fair value.
Threat
Debt is not well covered by operating cash flow.
Revenue is forecast to grow slower than 20% per year.
Next Steps:
Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Gerresheimer, we've compiled three pertinent aspects you should further examine:
Risks: For example, we've discovered 4 warning signs for Gerresheimer (2 are potentially serious!) that you should be aware of before investing here. Future Earnings: How does GXI's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every German stock every day, so if you want to find the intrinsic value of any other stock just search here.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 12.04.25 07:00:27 |
Gerresheimer AG (GRRMF) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Organic Challenges |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Revenue: Increased by 11.6% from EUR466 million in Q1 2024 to EUR520 million in Q1 2025. Adjusted EBITDA: Grew by 13.1% from EUR81 million to nearly EUR92 million. Organic Revenue Decline: Down by 6.5% on a pro forma basis. Organic Adjusted EBITDA Decline: Decreased by 9.3% on a pro forma basis. Adjusted EBITDA Margin: Declined by 50 basis points to 17.6% organically. Adjusted EPS: Decreased from EUR0.65 to EUR0.46, a decline of 36.6% FX neutral. Free Cash Flow: Declined from minus EUR79 million to minus EUR141 million before M&A. Net Financial Debt: Increased from EUR948 million to EUR1.930 million. Leverage Ratio: Increased from 2.32 times to 3.97 times. Liquidity: Stands at EUR764 million, including cash position of EUR151 million and undrawn revolving credit facility of EUR613 million.
Warning! GuruFocus has detected 3 Warning Signs with GRRMF.
Release Date: April 11, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Gerresheimer AG (GRRMF) reported a significant revenue increase due to the acquisition of Bormioli Pharma, marking the largest acquisition in the company's history. The integration of Bormioli Pharma is expected to create a global moulded glass powerhouse, enhancing Gerresheimer's position in the pharma and biotech industry. The company projects sustainable profitable growth of 8% to 10% in the midterm, supported by new product lines and a shift to high-value products. Gerresheimer AG (GRRMF) is making significant investments in eco-friendly technology, such as the new hybrid furnace in Lohr, Germany, which reduces carbon emissions by 40%. The company has a strong order book and expects to return to organic growth from Q2 onwards, supporting its 2025 guidance.
Negative Points
Gerresheimer AG (GRRMF) experienced an organic revenue decline of 6.5% and an EBITDA decline of 9.3% in Q1 2025. The company faced softer demand in its moulded glass business, particularly in the cosmetics market. The Morganton facility in the US is still recovering from flooding, impacting production capacity. The adjusted EPS declined by 36.6% on an FX-neutral basis, reflecting challenges in the current financial environment. Free cash flow was negative in Q1, and the company expects to end the year with a free cash flow figure between minus EUR50 million and 0.
Q & A Highlights
Q: Can you provide an indication of Bormioli's profitability in Q1 and its contribution to your full-year margin of around 22%? A: Bernd Metzner, CFO: We don't comment on subsegment performance, but Bormioli's profitability slightly increased in Q1. We expect a positive contribution to margin accretion in the coming quarters.
Story Continues
Q: How should we think about potential tariffs with your global production network? A: Dietmar Siemssen, CEO: Our strategy to produce and source in-region mitigates tariff impacts. Products shipped from Mexico to the US are covered by USMCA, so tariffs have no real negative impact on us.
Q: Could you update us on the ongoing strategic review and any potential private equity interest? A: Dietmar Siemssen, CEO: We are working on the strategic review and integration of Bormioli. Talks are ongoing, but there's no change to the information previously provided to the market.
Q: What is the outlook for organic growth phasing in Q2 to Q4, and any updates on GLP-1 contracts? A: Bernd Metzner, CFO: We expect strong growth in the second half of the year, with positive growth in Q2. For GLP-1 contracts, we anticipate EUR300 million in related revenues this year, with a significant step-up next year.
Q: Can you confirm if you expect double-digit growth in Q2, and quantify the order growth in Q1? A: Dietmar Siemssen, CEO: We expect positive growth in Q2, with stronger growth in the second half. We don't disclose specific order intake figures, but it was much higher compared to the previous year.
Q: Could you provide more color on the order strength supporting Q2 sales and any pre-tariff-related stocking? A: Dietmar Siemssen, CEO: Order intake is strong, especially for high-value products like vials and cartridges. We haven't seen significant pre-tariff-related stocking.
Q: How is the moulded glass business expected to perform in the second half of 2025? A: Dietmar Siemssen, CEO: The pharma segment is stable, and the new furnace in Lohr will positively impact the second half. The cosmetic market remains soft, and we remain prudent in our outlook.
Q: Can you discuss the impact of Bormioli's integration on operating efficiency and costs for this year? A: Dietmar Siemssen, CEO: Integration is ongoing, focusing on high-value plastic solutions and moulded glass. We are progressing well with cost synergies in headquarters and functions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
View Comments |
| 11.04.25 12:31:28 |
Gerresheimer (ETR:GXI) Has Affirmed Its Dividend Of €1.25 |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
The board of Gerresheimer AG (ETR:GXI) has announced that it will pay a dividend on the 10th of June, with investors receiving €1.25 per share. Based on this payment, the dividend yield on the company's stock will be 2.3%, which is an attractive boost to shareholder returns.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Gerresheimer's Payment Could Potentially Have Solid Earnings Coverage
If the payments aren't sustainable, a high yield for a few years won't matter that much. Prior to this announcement, Gerresheimer's earnings easily covered the dividend, but free cash flows were negative. We think that cash flows should take priority over earnings, so this is definitely a worry for the dividend going forward.
Looking forward, earnings per share is forecast to rise by 106.2% over the next year. If the dividend continues on this path, the payout ratio could be 20% by next year, which we think can be pretty sustainable going forward.XTRA:GXI Historic Dividend April 11th 2025
See our latest analysis for Gerresheimer
Gerresheimer Has A Solid Track Record
Even over a long history of paying dividends, the company's distributions have been remarkably stable. Since 2015, the annual payment back then was €0.75, compared to the most recent full-year payment of €1.25. This means that it has been growing its distributions at 5.2% per annum over that time. The growth of the dividend has been pretty reliable, so we think this can offer investors some nice additional income in their portfolio.
Dividend Growth May Be Hard To Achieve
Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Earnings per share has been crawling upwards at 4.3% per year. If Gerresheimer is struggling to find viable investments, it always has the option to increase its payout ratio to pay more to shareholders.
In Summary
Overall, we don't think this company makes a great dividend stock, even though the dividend wasn't cut this year. While the low payout ratio is a redeeming feature, this is offset by the minimal cash to cover the payments. We would be a touch cautious of relying on this stock primarily for the dividend income.
Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've identified 2 warning signs for Gerresheimer (1 doesn't sit too well with us!) that you should be aware of before investing. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments |
| 04.04.25 17:29:11 |
US Trade War Hits Billions of Dollars of Deals in 24 Hours |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
(Bloomberg) -- Donald Trump’s trade war has hit billions of dollars worth of potential mergers, acquisitions and initial public offerings in less than 24 hours.
Most Read from Bloomberg
Housing Agency Aims to Relocate Its DC Headquarters Metro-North Is Faster Than Acela on NYC-New Haven Route After Signal Updates Local Governments Vie for Fired Federal Workers London Clears Final Hurdle for More High-Speed Trains to Europe What Would ‘Transportation Abundance’ Look Like?
Ticket platform StubHub Holdings Inc., digital payments company Klarna Bank AB, adtech group MNTN Inc. and insurer Ategrity Specialty Holdings have all pressed pause on planned listings, according to people familiar with the matter, who asked not to be identified discussing confidential information. Their decisions come as markets extend deep losses in the wake of Trump’s move on Wednesday to impose the steepest American tariffs in a century.
A senior executive working in the IPO industry said they expected all listings to be delayed for at least the next two weeks. The person didn’t expect any companies to launch investor roadshows amid the market volatility.
Fintech company Chime is pushing back filing its financials with regulators, also delaying its IPO, the Wall Street Journal reported Friday, citing people familiar with the matter.
The global stock rout is also affecting M&A markets. Bloomberg News reported Friday that French building materials producer Cie. de Saint-Gobain has decided to hold off on a sale of its auto glass unit, which could have fetched as much as €2.5 billion ($2.8 billion). Elsewhere amid the turmoil, private equity firm KKR & Co. has walked away from a consortium discussing a takeover of Gerresheimer AG, the German maker of packaging for drugs and cosmetics that has a market capitalization of about €2 billion.
Other agreed transactions could also be under threat. In the leveraged finance markets, debt being sold to back deals such as HIG Capital’s purchase of Canadian firm Converge Technology Solutions Corp. and ABC Technologies Holdings Inc.’s acquisition of TI Fluid Systems Plc have been delayed, Bloomberg News has reported.
Fresh Blow
Trump’s tariffs have sparked early retaliation, with China announcing commensurate levies on all American goods and export controls on rare earths. The European Union, the US’s largest trading partner, has also vowed action. The S&P 500 fell as much as 5.5% on Friday.
The fallout is a fresh blow to dealmakers, who’d been hoping for a banner year under Trump 2.0 only to find themselves disappointed by the uncertainty created by the president’s sweeping policy changes. Global M&A activity was sluggish throughout the first quarter and equity bankers were starting to worry that highly-anticipated initial public offerings could end up getting jammed.
Story Continues
This was already affecting transactions.
Suitors for a package of homecare brands being sold by Reckitt Benckiser Group Plc have been trying to figure out how Trump’s tariffs will affect the assets, people with knowledge of the matter said previously. Court Square Capital Partners was planning to sell portfolio company Golden State Medical Supply, which provides generic drugs to the federal health system, but shelved those plans due to uncertainties around tariffs and other unknowns. And Rosebank Industries Plc pulled out of a $2 billion acquisition, blaming market volatility. A €1.5 billion listing of German drugmaker Stada Arzneimittel AG, which had been expected to kick-start IPO activity in Europe, was delayed for the same reason.
--With assistance from Lauren Tara LaCapra, Maggie Eastland, Ryan Gould, Dinesh Nair, Gillian Tan, Bailey Lipschultz and Katie Roof.
(Adds detail on Ategrity in second paragraph, updates S&P fall in seventh paragraph.)
Most Read from Bloomberg Businessweek
With Shake Shack in First Class, Airline Food Is No Longer a Joke LA Fire Victims Are Betting on a Radical Idea to Help Them Rebuild India’s Destination Weddings Fuel a New Tourist Economy China Tells Kids to Study Manufacturing to Fill Factory Jobs Trump’s IRS Cuts Are Tempting Taxpayers to Cheat
©2025 Bloomberg L.P.
View Comments |
| 04.04.25 15:11:45 |
European Stocks Head for Correction After China Tariffs Response |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
(Bloomberg) -- European stocks plunged toward a correction as China retaliated against US tariffs, escalating the global trade war.
Most Read from Bloomberg
Housing Agency Aims to Relocate Its DC Headquarters Metro-North Is Faster Than Acela on NYC-New Haven Route After Signal Updates Local Governments Vie for Fired Federal Workers London Clears Final Hurdle for More High-Speed Trains to Europe What Would ‘Transportation Abundance’ Look Like?
The Stoxx Europe 600 Index slid as much as 5.9%, with the benchmark set for its worst weekly drop since the outbreak of the Covid-19 pandemic five years ago.
Indexes in Italy, France, Switzerland and Germany were also in correction territory after news that Beijing would impose a 34% tariff on all imports from the US starting April 10.
Banks were the biggest laggards, with the Stoxx 600 Banks Index sinking as much as 10%. Italy’s FTSE MIB Index — largely comprised of lenders — led losses among major European benchmarks with a 8% slide.
“Every portfolio has to adjust themselves for a recession in a lot of countries,” said David Kruk, head of trading at La Financiere de L’Echiquier. “Yesterday, the US bore the brunt of the selloff. Now it’s our turn,” he added.
Still, data showing better-than-expected US job growth in March was somewhat reassuring, according to Amelie Derambure, senior multi-asset portfolio manager at Amundi SA.
“If the data had been really bad, it would have led to the conclusion that the Trump administration and the uncertainty around its policies were already triggering a recession,” said Derambure.
Traders had earlier boosted their expectations for the US Federal Reserve to cut interest rates this year.
Among individual stock movers, Gerresheimer AG fell as much as 21% after Bloomberg News reported KKR & Co. has walked away from a consortium discussing a takeover of the German maker of drug packaging.
Here is what market participants are saying:
Max Kettner, HSBC chief multi-asset strategist:
“We don’t think the correction is over yet. In fact our measures of sentiment and positioning are still ambiguous at best. Our momentum signals indicate that typical trend-following strategies are still only medium short, and equity exposure on our measure of long-only investors has barely budged so far. Equity market breadth in the S&P500 is nowhere near capitulation levels yet, and in fact is even still much higher than during the rates-driven dip in January. The average stock has actually been flat YTD until yesterday, so we do think there’s quite a bit more pain to come until the Fed put can step in”
Story Continues
Vincent Juvyns, global market strategist at JPMorgan Asset Management:
“Let me be clear, in no way is this capitulation, it’s a slap in the face but this is not capitulation. Indeed you can see that it’s the best performing stocks and indexes that are falling the most, like banks, because that’s where investors can take their profits. But let me be clear and I say that with conviction: for a long term investors, this selloff creates a lot of buying opportunities. The selloff is overdone in my opinion. Yes there’s going to be macro-economic consequences to the tariffs but my point is that for diversified investors, bonds are perfectly doing their job in cushioning the fall in equities”
Neil Birrell, chief investment officer at Premier Miton Investors:
“The bifurcation you’re getting within different markets is extraordinary. Within equities, it’s get out of anything that’s rate-sensitives, get into safety”
Aneeka Gupta, head of macroeconomic research at Wisdom Tree UK Ltd:
“It’s unprecedented to see this in the second day in a row. China’s response is predominantly setting the stage. The likelihood now is that if with China leading the way, we’re likely to get more countermeasures being put in place by other economies. Right now for market, you could compare it with catching a falling knife. It’s quite a difficult situation”
Janet Mui, head of market analysis at RBC Brewin Dolphin:
“I think people are fleeing for safety now because the situation appears to be spiraling downward. It is hard to see a scenario where most of the tariffs will be rolled back in the near term. The sentiment shock is going to inflict a lot of harm for both the U.S. and elsewhere”
Raphael Thuin, head of capital markets strategies at Tikehau Capital:
“Today we’ve entered an escalation phase with countries starting to retaliate and it’s not possible to know how this will end. We must get used to the idea that this a regime change: growth expectations will be cut down and inflation forecast revised upwards. Even if one ignores for a minute the immediate market action, long term, the horizon has darkened. What’s also worrying is that central banks won’t be in a position to weigh in that much given that this new cycle is an inflationary one”
Susana Cruz, Panmure Liberum strategist:
“It looks like investors are playing it safe, with the announcement of Chinese retaliations adding to the already growing recession risks. They seem to be bracing for more bad news, as sectors with strong momentum before the tariffs, like European banks and industrials, face a deeper selloff. Quality stocks and low volatility are providing some shelter amid the storm.”
For more on equity markets:
Timing to Go Defensive Has Rarely Been Better: Taking Stock M&A Watch Europe: KKR, Gerresheimer, Carrefour, Shell, BTG, BP Gulf Listings Feeling the Heat on Earnings Misses: ECM Watch US Stock Futures Fall as Sentiment Remains Fragile on Tariffs Trump’s 10% Slap: The London Rush
You want more news on this market? Click here for a curated First Word channel of actionable news from Bloomberg and select sources. It can be customized to your preferences by clicking into Actions on the toolbar or hitting the HELP key for assistance. To subscribe to a daily list of European analyst rating changes, click here.
--With assistance from Sagarika Jaisinghani, Allegra Catelli, Levin Stamm and Paul Jarvis.
Most Read from Bloomberg Businessweek
With Shake Shack in First Class, Airline Food Is No Longer a Joke LA Fire Victims Are Betting on a Radical Idea to Help Them Rebuild India’s Destination Weddings Fuel a New Tourist Economy China Tells Kids to Study Manufacturing to Fill Factory Jobs Trump’s IRS Cuts Are Tempting Taxpayers to Cheat
©2025 Bloomberg L.P.
View Comments |
| 03.04.25 19:54:40 |
KKR drops out of consortium seeking Gerresheimer takeover, Bloomberg News reports |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
(Reuters) -KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG, Bloomberg News reported on Thursday, citing people familiar with the matter.
Warburg Pincus, which was also a part of the consortium, is still working to see if it can reach a deal, the report said.
Earlier this month, Reuters reported that a consortium including KKR and Warburg Pincus had submitted a non-binding bid for Gerresheimer.
Gerresheimer, which makes pens used to inject weight-loss drugs such as Novo Nordisk's Wegovy, has a market capitalization of about 2.22 billion euros, according to LSEG data.
The consortium had submitted a bid at about 90 euros a share, which would value the company at nearly 3.1 billion euros ($3.42 billion).
KKR and Gerresheimer did not immediately respond to Reuters' requests for comment, while Warburg Pincus declined to comment.
In February, the German company said it was in early-stage discussions with private equity investors over a potential sale of the company.
Gerresheimer said at that time that the interest was informal and on a non-binding basis.
($1 = 0.9065 euros)
(Reporting by Pretish M J in Bengaluru; Editing by Alan Barona and Maju Samuel)
View Comments |
